Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD

NCT: NCT07770867 · NOT_YET_RECRUITING

NCT IDNCT07770867
StatusNOT_YET_RECRUITING
Start Date2026-08
Completion2027-09
SponsorNeudive Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to evaluate the safety of NDTx-03 used together with treatment as usual (TAU) and to determine whether NDTx-03 plus TAU is more effective than TAU alone in improving social situation recognition and interaction in children and adolescents with autism spectrum disorder (ASD) or social communication disorder (SCD).

Frequently Asked Questions

What is Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD?

Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD is a clinical trial registered under NCT07770867. Current status: NOT_YET_RECRUITING.

What is the status of NCT07770867?

The current status of NCT07770867 (Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD) is: NOT_YET_RECRUITING.

When did Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD start?

Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD started on 2026-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.